内容紹介
Novel Method of Determination of Δ9-Tetrahydrocannabinol(THC) in Human Serum by High-Performance Liquid Chromatography with Electrochemical Detection
Summary
In Europe and the United States, Δ9-tetrahydrocannabinol(THC, dronabinol), one of the psychoactive constituents of cannabis, has been used for both its anti-emetic and orexigenic effects in cancer patient receiving chemotherapy. However, dronabinol has not yet been launched in the market in Japan. In the future, it is necessary to ascertain the pharmacokinetics of dronabinol in cancer paitient. Therefore, we developed an HPLC procedure using electrochemical detection(ECD)for quantitation of the concentrations of dronabinol in blood. An eluent of 50 mM KH2PO4/CH3CN(9 :16)was used as the mobile phase. The column was used the XTerra® RP18, and the voltage of the electrochemical detector in dronabinol was set at 400 mV. As a result, the calibration curve was linear in the range of 10 ng/mL to 100 ng/mL(y=964.85x-3,419, r=0.997). The lower limit of quantification was 0.5 ng/mL(S/N=3). The relative within-runs and between-runs standard deviations for the assay dronabinol were less than 4.7%. The method reported here is superior to previously reported methods in cancer patient.
要旨
ドロナビノール(Δ-9THC)は欧米諸国において,がん化学療法の制吐および食欲増進を目的として使用されているが,本邦では未だ上市されていない。がん患者の苦痛を緩和させるためには本邦においても必要性が高く,その導入に向け今回,HPLC/ECDによりドロナビノール血中濃度測定法の開発を試みた。カラムはXTerra® RP18,測定電位は400 mVに設定した。移動相は50 mM KH2PO4/CH3CN(9 :16)とし,1.0 mL/minの流速で行った。検量線は10～100 ng/mLの範囲内でy=964.85x-3,419(r=0.997)と良好であり,検出限界は0.5 ng/mL(S/N=3)であった。日差および日内変動は4.7%以下と良好であった。今回,がん患者にドロナビノールを適正に使用するための血中濃度測定法が開発された。
目次
癌と化学療法 TOPへ
癌と化学療法 41巻4号 2014年4月号トップへ
【原著】
▶Novel Method of Determination of Δ9-Tetrahydrocannabinol(THC)in Human Serum by High-Performance Liquid Chromatography with Electrochemical Detection…国分 秀也ほか
Summary
In Europe and the United States, Δ9-tetrahydrocannabinol(THC, dronabinol), one of the psychoactive constituents of cannabis, has been used for both its anti-emetic and orexigenic effects in cancer patient receiving chemotherapy. However, dronabinol has not yet been launched in the market in Japan. In the future, it is necessary to ascertain the pharmacokinetics of dronabinol in cancer paitient. Therefore, we developed an HPLC procedure using electrochemical detection(ECD)for quantitation of the concentrations of dronabinol in blood. An eluent of 50 mM KH2PO4/CH3CN(9 :16)was used as the mobile phase. The column was used the XTerra® RP18, and the voltage of the electrochemical detector in dronabinol was set at 400 mV. As a result, the calibration curve was linear in the range of 10 ng/mL to 100 ng/mL(y=964.85x-3,419, r=0.997). The lower limit of quantification was 0.5 ng/mL(S/N=3). The relative within-runs and between-runs standard deviations for the assay dronabinol were less than 4.7%. The method reported here is superior to previously reported methods in cancer patient.
要旨
ドロナビノール(Δ-9THC)は欧米諸国において,がん化学療法の制吐および食欲増進を目的として使用されているが,本邦では未だ上市されていない。がん患者の苦痛を緩和させるためには本邦においても必要性が高く,その導入に向け今回,HPLC/ECDによりドロナビノール血中濃度測定法の開発を試みた。カラムはXTerra® RP18,測定電位は400 mVに設定した。移動相は50 mM KH2PO4/CH3CN(9 :16)とし,1.0 mL/minの流速で行った。検量線は10～100 ng/mLの範囲内でy=964.85x-3,419(r=0.997)と良好であり,検出限界は0.5 ng/mL(S/N=3)であった。日差および日内変動は4.7%以下と良好であった。今回,がん患者にドロナビノールを適正に使用するための血中濃度測定法が開発された。